U.S. markets closed
  • S&P Futures

    4,258.50
    +2.50 (+0.06%)
     
  • Dow Futures

    34,196.00
    +114.00 (+0.33%)
     
  • Nasdaq Futures

    14,343.75
    -10.50 (-0.07%)
     
  • Russell 2000 Futures

    2,334.90
    +3.70 (+0.16%)
     
  • Crude Oil

    73.47
    +0.17 (+0.23%)
     
  • Gold

    1,774.80
    -1.90 (-0.11%)
     
  • Silver

    25.99
    -0.06 (-0.23%)
     
  • EUR/USD

    1.1939
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    15.97
    -0.35 (-2.14%)
     
  • GBP/USD

    1.3914
    -0.0007 (-0.05%)
     
  • USD/JPY

    110.9740
    +0.1390 (+0.13%)
     
  • BTC-USD

    34,717.73
    +1,289.23 (+3.86%)
     
  • CMC Crypto 200

    837.69
    +51.07 (+6.49%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    29,077.62
    +202.39 (+0.70%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FGEN, CS and CCXI

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

FibroGen, Inc. (NASDAQ:FGEN)
Class Period: November 8, 2019 - April 6, 2021
Lead Plaintiff Deadline: June 11, 2021

Throughout the class period, FibroGen, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in FGEN: http://www.kleinstocklaw.com/pslra-1/fibrogen-inc-loss-submission-form?id=15579&from=1

Credit Suisse Group AG (NYSE:CS)
Class Period: October 29, 2020 - March 31, 2021
Lead Plaintiff Deadline: June 15, 2021

The CS lawsuit alleges Credit Suisse Group AG made materially false and/or misleading statements and/or failed to disclose during the class period that: defendants concealed material defects in the Company's risk policies and procedures and compliance oversight functions and efforts to allow high-risk clients to take on excessive leverage, including Greensill Capital (“Greensill”) and Archegos Capital Management (“Archegos”), exposing the Company to billions of dollars in losses.

Learn about your recoverable losses in CS: http://www.kleinstocklaw.com/pslra-1/credit-suisse-group-ag-loss-submission-form?id=15579&from=1

ChemoCentryx, Inc. (NASDAQ:CCXI)
Class Period: November 26, 2019 - May 3, 2021
Lead Plaintiff Deadline: July 6, 2021

During the class period, ChemoCentryx, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in CCXI: http://www.kleinstocklaw.com/pslra-1/chemocentryx-inc-loss-submission-form?id=15579&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/645588/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-FGEN-CS-and-CCXI